Literature DB >> 29688786

Comparison of the efficacy of various concentrations and combinations of serum, ethylenediaminetetraacetic acid, tetracycline, doxycycline, minocycline, and N-acetylcysteine for inhibition of collagenase activity in an in vitro corneal degradation model.

Beth A Kimmitt, George E Moore, Jean Stiles.   

Abstract

OBJECTIVE To compare the efficacy of various concentrations and combinations of serum, EDTA, 3 tetracyclines, and N-acetylcysteine (NAC) for collagenase inhibition in an in vitro corneal degradation model. SAMPLE Grossly normal corneas from recently euthanized dogs and horses and fresh serum from healthy dogs and horses. PROCEDURES Serum was pooled by species for in vitro use. For each species, sections of cornea were dried, weighed, and incubated with clostridial collagenase (800 U/mL) in 5 mL of a 5mM calcium chloride-saline (0.9% NaCl) incubation solution and 500 μL of 1 of 19 treatments (homologous serum; 0.3%, 1.0%, or 2% EDTA; 0.1%, 0.5%, or 1.0% tetracycline, doxycycline, or minocycline; 0.5%, 1.0%, or 5.0% NAC; serum with 0.5% tetracycline; serum with 1.0% EDTA; or 1.0% EDTA with 0.5% tetracycline). Positive and negative control specimens were incubated with 5 mL of incubation solution with and without collagenase, respectively. Each control and treatment was replicated 4 times for each species. Following incubation, corneal specimens were dried and reweighed. The percentage corneal degradation was calculated and compared among treatments within each species. RESULTS Treatments with tetracyclines at concentrations ≥ 0.5%, with EDTA at concentrations ≥ 0.3%, and with NAC at concentrations ≥ 0.5% were more effective at preventing corneal degradation than serum in both species. The efficacy of each combination treatment was equal to or less than that of its components. CONCLUSIONS AND CLINICAL RELEVANCE Results suggested EDTA, tetracyclines, and NAC may be beneficial for topical treatment of keratomalacia, but in vivo studies are required.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29688786     DOI: 10.2460/ajvr.79.5.555

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  2 in total

1.  Oral doxycycline prevents skin-associated adverse effects induced by injectable collagenase in a rodent model of capsular contracture around silicone implants.

Authors:  Yannick F Diehm; Dimitra Kotsougiani-Fischer; Elena Porst; Valentin Haug; Laura C Siegwart; Daniel Overhoff; Ulrich Kneser; Sebastian Fischer
Journal:  PLoS One       Date:  2022-07-06       Impact factor: 3.752

2.  Doxycycline Reduces Scar Thickness and Improves Collagen Architecture.

Authors:  Alessandra L Moore; Heather E desJardins-Park; Bryan A Duoto; Shamik Mascharak; Matthew P Murphy; Dre M Irizarry; Deshka S Foster; Ruth E Jones; Leandra A Barnes; Clement D Marshall; Ryan C Ransom; Gerlinde Wernig; Michael T Longaker
Journal:  Ann Surg       Date:  2020-07       Impact factor: 13.787

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.